In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...